FINWIRES · TerminalLIVE
FINWIRES

$GMAB

5 stories mentioning GMAB

Every FINWIRES story that references GMAB, newest first.

Wire

Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits

Genmab (GMAB) said Thursday that new data from a post-hoc subgroup analysis of its phase 3 Epcore FL-1 trial showed that in adult patients with relapsed or refractory follicular lymphoma, epcoritamab in combination with rituximab and lenalidomide showed "consistent and sustained efficacy benefits" across clinically relevant subgroups.The new data included a Follicular Lymphoma International Prognostic Index score of 0-2 versus 3-5 previously, progression of disease less than or equal to two years from the date of initial frontline therapy POD24, and patient fitness, the company said.The safety profile of epcoritamab in combination with rituximab and lenalidomide was "manageable" across all patient subgroups and consistent with that observed in the overall trial population, with no new safety signals identified, the company added.The results will be presented during an oral presentation at the European Hematology Association 2026 Congress held in Stockholm, the company said.Price: $24.94, Change: $+0.45, Percent Change: +1.82%

$GMAB
Wire

Genmab Q1 Net Profit Falls, Revenue Rises

Genmab (GMAB) reported Thursday a Q1 net profit of $0.83 per diluted share, down from $3.05 a year earlier.Analysts polled by FactSet expected $0.16.Revenue for the three months ended March 31 was $896 million, up from $715 million a year earlier.Analysts surveyed by FactSet expected $905.8 million.The firm kept its 2026 financial guidance, including for revenue of $4.07 billion to $4.40 billion. Analysts expect $4.33 billion.Shares were down over 3% in afternoon trading.Price: $27.04, Change: $-0.85, Percent Change: -3.05%

$GMAB
Research

Goldman Sachs Upgrades Genmab to Buy From Neutral, Adjusts Price Target to $30.50 From $24.50

Genmab A/S (GMAB) has an average rating of buy and mean price target of $37.62, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$GMAB
Sectors

Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday

Health care stocks were flat to higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) up 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) inactive.Novo Nordisk (NVO) has received the Medicines and Healthcare products Regulatory Agency approval for a new single-dose 7.2 mg of Wegovy to treat adults with obesity, the UK regulator said. Shares of Novo Nordisk were up more than 3% pre-bell.Johnson & Johnson (JNJ) stock was down more than 1% after the company posted a decline in Q1 adjusted earnings.Genmab (GMAB) shares were up more than 2% after the company reported Q1 DARZALEX net sales Tuesday of about $4 million, including $2.2 million in the US and $1.8 million in the rest of the world.

$GMAB$IBB$JNJ$NVO$XLV
Wire

Genmab Says Rinatabart Sesutecan Combination Tolerable in Patients With Advanced Ovarian Cancer

Genmab (GMAB) said Monday that data from a phase 1/2 Rainfol-01 trial demonstrated that rinatabart sesutecan in combination with bevacizumab was tolerable and showed no new safety signals in patients with advanced ovarian cancer.The most common treatment-emergent adverse events, or TAEs, under the 40-patient trial included nausea, fatigue, anemia, and neutropenia. Serious TAEs occurred in six patients, while TAEs leading to rinatabart sesutecan dose reductions occurred in 11 patients and bevacizumab discontinuation occurred in two patients, the company said.

$GMAB